Viveve Medical Inc
Change company Symbol lookup
Select an option...
VIVE Viveve Medical Inc
RF Regions Financial Corp
QRVO Qorvo Inc
PRTY Party City Holdco Inc
PLAY Dave & Buster's Entertainment Inc
PH Parker-Hannifin Corp
PEN Penumbra Inc
PDFS PDF Solutions Inc
PBH Prestige Consumer Healthcare Inc
PB Prosperity Bancshares Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

Closing Price
$0.6312
Day's Change
-0.0088 (-1.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.6449
Day's Low
0.61
Volume
(Light)
Volume:
703,789

10-day average volume:
1,234,160
703,789

Company Profile

Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
1.96x
Price/Book (MRQ)
0.50x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

May 2020
Current Month
360.8K
Previous Month
372.3K
Percent of Float
2.39%
Days to Cover
0.3000 Days

Share Information

VIVE is in a share class of common stock
Float
15.1M
Shares Outstanding
15.1M
Institutions Holding Shares
13
0.86%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Steven L. BastaChmn.
  • James G. AtkinsonPres.
  • Scott C. DurbinCEO
  • Jim B. RobbinsCFO
  • Debora A. JornDir.

Address

  • 345 Inverness Dr S Bldg B Ste 250
  • Englewood, CO 80112-5889
  • Phone: (408) 530-1900
  • Fax: (302) 655-5049
  • https://us.viveve.com/

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.